Aardvark Therapeutics Q2 EPS $(0.66) Beats $(0.91) Estimate
Aardvark Therapeutics (NASDAQ:AARD) reported quarterly losses of $(0.66) per share which beat the analyst consensus estimate of $(0.91) by 27.47 percent. This is unchanged from the same period last year.
Aardvark lost less money per share than experts predicted, which is good news. When a company does better than people expected, it can signal the business is moving in the right direction—keep watching if they keep improving.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.